Kawasaki disease

This trial compares two blood thinners—rivaroxaban (Xarelto) and warfarin—in children over 2 years old who have giant coronary artery aneurysms caused by Kawasaki disease. The goal is to see if rivaroxaban is safer and as effective as warfarin at preventing blood clots, major ble…

This phase 3 trial is testing whether atorvastatin, a common cholesterol drug, is safe and can reduce inflammation in children with Kawasaki disease who also have coronary artery abnormalities. The study will enroll 9 children and give them different doses of atorvastatin for 6 w…

This pilot study tests the blood thinner Rivaroxaban in 10 Chinese children who developed giant coronary artery aneurysms after Kawasaki disease. The goal is to see if a specially adjusted dose can prevent new blood clots in the heart arteries while keeping bleeding risks low. Ch…

This study is testing a computer tool called Kawasaki MATCH that helps doctors decide if a child with fever has Kawasaki Disease. The tool uses patient age, lab results, and symptoms to give a risk score. Researchers want to see if using this tool leads to faster treatment. About…

This study is collecting blood and other samples from 5,000 children and young adults (under 21) who are already taking certain medications as part of their regular care. The goal is to understand how these drugs move through and affect children's bodies, so doctors can prescribe…

This study looks at two scoring tools (Kobayashi and Kawanet) to see if they can identify children with Kawasaki disease who are likely to resist standard IVIG treatment. About 10-20% of children don't respond to IVIG and face a higher risk of heart problems. Researchers will enr…

This study is following 670 adults with vasculitis, a rare blood vessel disease, for up to 5 years. Researchers will collect medical data and blood samples to see how the disease starts, how it is treated, and what long-term problems may arise. No new treatments are being tested—…